<html>
    <head>
        <meta charset="utf-8">
        
            <script src="lib/bindings/utils.js"></script>
            <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/vis-network/9.1.2/dist/dist/vis-network.min.css" integrity="sha512-WgxfT5LWjfszlPHXRmBWHkV2eceiWTOBvrKCNbdgDYTHrT2AeLCGbF4sZlZw3UMN3WtL0tGUoIAKsu8mllg/XA==" crossorigin="anonymous" referrerpolicy="no-referrer" />
            <script src="https://cdnjs.cloudflare.com/ajax/libs/vis-network/9.1.2/dist/vis-network.min.js" integrity="sha512-LnvoEWDFrqGHlHmDD2101OrLcbsfkrzoSpvtSQtxK3RMnRV0eOkhhBN2dXHKRrUU8p2DGRTk35n4O8nWSVe1mQ==" crossorigin="anonymous" referrerpolicy="no-referrer"></script>
            
        
<center>
<h1></h1>
</center>

<!-- <link rel="stylesheet" href="../node_modules/vis/dist/vis.min.css" type="text/css" />
<script type="text/javascript" src="../node_modules/vis/dist/vis.js"> </script>-->
        <link
          href="https://cdn.jsdelivr.net/npm/bootstrap@5.0.0-beta3/dist/css/bootstrap.min.css"
          rel="stylesheet"
          integrity="sha384-eOJMYsd53ii+scO/bJGFsiCZc+5NDVN2yr8+0RDqr0Ql0h+rP48ckxlpbzKgwra6"
          crossorigin="anonymous"
        />
        <script
          src="https://cdn.jsdelivr.net/npm/bootstrap@5.0.0-beta3/dist/js/bootstrap.bundle.min.js"
          integrity="sha384-JEW9xMcG8R+pH31jmWH6WWP0WintQrMb4s7ZOdauHnUtxwoG2vI5DkLtS3qm9Ekf"
          crossorigin="anonymous"
        ></script>


        <center>
          <h1></h1>
        </center>
        <style type="text/css">

             #mynetwork {
                 width: 100%;
                 height: 750px;
                 background-color: #ffffff;
                 border: 1px solid lightgray;
                 position: relative;
                 float: left;
             }

             
             #loadingBar {
                 position:absolute;
                 top:0px;
                 left:0px;
                 width: 100%;
                 height: 750px;
                 background-color:rgba(200,200,200,0.8);
                 -webkit-transition: all 0.5s ease;
                 -moz-transition: all 0.5s ease;
                 -ms-transition: all 0.5s ease;
                 -o-transition: all 0.5s ease;
                 transition: all 0.5s ease;
                 opacity:1;
             }

             #bar {
                 position:absolute;
                 top:0px;
                 left:0px;
                 width:20px;
                 height:20px;
                 margin:auto auto auto auto;
                 border-radius:11px;
                 border:2px solid rgba(30,30,30,0.05);
                 background: rgb(0, 173, 246); /* Old browsers */
                 box-shadow: 2px 0px 4px rgba(0,0,0,0.4);
             }

             #border {
                 position:absolute;
                 top:10px;
                 left:10px;
                 width:500px;
                 height:23px;
                 margin:auto auto auto auto;
                 box-shadow: 0px 0px 4px rgba(0,0,0,0.2);
                 border-radius:10px;
             }

             #text {
                 position:absolute;
                 top:8px;
                 left:530px;
                 width:30px;
                 height:50px;
                 margin:auto auto auto auto;
                 font-size:22px;
                 color: #000000;
             }

             div.outerBorder {
                 position:relative;
                 top:400px;
                 width:600px;
                 height:44px;
                 margin:auto auto auto auto;
                 border:8px solid rgba(0,0,0,0.1);
                 background: rgb(252,252,252); /* Old browsers */
                 background: -moz-linear-gradient(top,  rgba(252,252,252,1) 0%, rgba(237,237,237,1) 100%); /* FF3.6+ */
                 background: -webkit-gradient(linear, left top, left bottom, color-stop(0%,rgba(252,252,252,1)), color-stop(100%,rgba(237,237,237,1))); /* Chrome,Safari4+ */
                 background: -webkit-linear-gradient(top,  rgba(252,252,252,1) 0%,rgba(237,237,237,1) 100%); /* Chrome10+,Safari5.1+ */
                 background: -o-linear-gradient(top,  rgba(252,252,252,1) 0%,rgba(237,237,237,1) 100%); /* Opera 11.10+ */
                 background: -ms-linear-gradient(top,  rgba(252,252,252,1) 0%,rgba(237,237,237,1) 100%); /* IE10+ */
                 background: linear-gradient(to bottom,  rgba(252,252,252,1) 0%,rgba(237,237,237,1) 100%); /* W3C */
                 filter: progid:DXImageTransform.Microsoft.gradient( startColorstr='#fcfcfc', endColorstr='#ededed',GradientType=0 ); /* IE6-9 */
                 border-radius:72px;
                 box-shadow: 0px 0px 10px rgba(0,0,0,0.2);
             }
             

             

             
        </style>
    </head>


    <body>
        <div class="card" style="width: 100%">
            
            
            <div id="mynetwork" class="card-body"></div>
        </div>

        
            <div id="loadingBar">
              <div class="outerBorder">
                <div id="text">0%</div>
                <div id="border">
                  <div id="bar"></div>
                </div>
              </div>
            </div>
        
        

        <script type="text/javascript">

              // initialize global variables.
              var edges;
              var nodes;
              var allNodes;
              var allEdges;
              var nodeColors;
              var originalNodes;
              var network;
              var container;
              var options, data;
              var filter = {
                  item : '',
                  property : '',
                  value : []
              };

              

              

              // This method is responsible for drawing the graph, returns the drawn network
              function drawGraph() {
                  var container = document.getElementById('mynetwork');

                  

                  // parsing and collecting nodes and edges from the python
                  nodes = new vis.DataSet([{"color": "lightblue", "font": {"color": "black"}, "id": "ARTICLE::A Perspective on Ovarian Cancer Biomarkers: Past, Present and Yet-To-Come", "label": "A Perspective on Ovarian Cancer Biomarkers: Past, Present and Yet-To-Come", "shape": "box"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::FREE DNA", "label": "FREE DNA", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::CIRCULATING TUMOR DNA (CTDNA)", "label": "CIRCULATING TUMOR DNA (CTDNA)", "shape": "ellipse"}, {"color": "lightblue", "font": {"color": "black"}, "id": "ARTICLE::AhRR and PPP1R3C: Potential Prognostic Biomarkers for Serous Ovarian Cancer", "label": "AhRR and PPP1R3C: Potential Prognostic Biomarkers for Serous Ovarian Cancer", "shape": "box"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::5P15.33", "label": "5P15.33", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::CHROMOSOME 5", "label": "CHROMOSOME 5", "shape": "ellipse"}, {"color": "lightblue", "font": {"color": "black"}, "id": "ARTICLE::RNA biomarkers from proximal liquid biopsy for diagnosis of ovarian cancer", "label": "RNA biomarkers from proximal liquid biopsy for diagnosis of ovarian cancer", "shape": "box"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::20Q12-Q13", "label": "20Q12-Q13", "shape": "ellipse"}, {"color": "lightblue", "font": {"color": "black"}, "id": "ARTICLE::Recent Advances in Ovarian Cancer: Therapeutic Strategies, Potential Biomarkers, and Technological Improvements", "label": "Recent Advances in Ovarian Cancer: Therapeutic Strategies, Potential Biomarkers, and Technological Improvements", "shape": "box"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::CPG ISLAND", "label": "CPG ISLAND", "shape": "ellipse"}, {"color": "lightblue", "font": {"color": "black"}, "id": "ARTICLE::Recent Insight about HE4 Role in Ovarian Cancer Oncogenesis", "label": "Recent Insight about HE4 Role in Ovarian Cancer Oncogenesis", "shape": "box"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::CHROMOSOME 20Q12-13.1", "label": "CHROMOSOME 20Q12-13.1", "shape": "ellipse"}, {"color": "lightblue", "font": {"color": "black"}, "id": "ARTICLE::Role of Circulating Biomarkers in Platinum-Resistant Ovarian Cancer", "label": "Role of Circulating Biomarkers in Platinum-Resistant Ovarian Cancer", "shape": "box"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::CHROMOSOME 16P13.3", "label": "CHROMOSOME 16P13.3", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::CHROMOSOME 17", "label": "CHROMOSOME 17", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::CPG SITES", "label": "CPG SITES", "shape": "ellipse"}, {"color": "lightblue", "font": {"color": "black"}, "id": "ARTICLE::Role of biomarkers for early detection of ovarian cancer \r\nrecurrence", "label": "Role of biomarkers for early detection of ovarian cancer \r\nrecurrence", "shape": "box"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::CDNA", "label": "CDNA", "shape": "ellipse"}, {"color": "lightblue", "font": {"color": "black"}, "id": "ARTICLE::Role of different non-coding RNAs as ovarian Cancer biomarkers", "label": "Role of different non-coding RNAs as ovarian Cancer biomarkers", "shape": "box"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::H19_CHR11P15.5", "label": "H19_CHR11P15.5", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::HOTAIR_CHR12Q13.13", "label": "HOTAIR_CHR12Q13.13", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::XIST_CHRX", "label": "XIST_CHRX", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::UCA1_CHR19P13.12", "label": "UCA1_CHR19P13.12", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::MALAT1_CHR11Q13", "label": "MALAT1_CHR11Q13", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::PVT1_CHR8Q24.21", "label": "PVT1_CHR8Q24.21", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::GAS5_1Q25.1.10", "label": "GAS5_1Q25.1.10", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::HOXD-AS1_CHR2Q31.2", "label": "HOXD-AS1_CHR2Q31.2", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::SPRY4-IT1_CHR5Q31.3", "label": "SPRY4-IT1_CHR5Q31.3", "shape": "ellipse"}, {"color": "lightblue", "font": {"color": "black"}, "id": "ARTICLE::Role of lncRNAs in ovarian cancer: defining new biomarkers for therapeutic purposes", "label": "Role of lncRNAs in ovarian cancer: defining new biomarkers for therapeutic purposes", "shape": "box"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::CHROMOSOME 1", "label": "CHROMOSOME 1", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::8Q24", "label": "8Q24", "shape": "ellipse"}, {"color": "lightblue", "font": {"color": "black"}, "id": "ARTICLE::Analysis of Circulating Tumor Cells in \r\nOvarian Cancer and Their Clinical Value as a \r\nBiomarker", "label": "Analysis of Circulating Tumor Cells in \r\nOvarian Cancer and Their Clinical Value as a \r\nBiomarker", "shape": "box"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::CIRCULATING FREE DNA", "label": "CIRCULATING FREE DNA", "shape": "ellipse"}, {"color": "lightblue", "font": {"color": "black"}, "id": "ARTICLE::Novel BRCA1 and BRCA2 Tumor Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas", "label": "Novel BRCA1 and BRCA2 Tumor Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas", "shape": "box"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::BRCA1 PROMOTER", "label": "BRCA1 PROMOTER", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::BRCA1 EXON 22", "label": "BRCA1 EXON 22", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::BRCA1 INTRON -20 TO +20", "label": "BRCA1 INTRON -20 TO +20", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::BRCA1 LOCUS", "label": "BRCA1 LOCUS", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::BRCA2 LOCUS", "label": "BRCA2 LOCUS", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::BRCA2 INTRON -20 TO +20", "label": "BRCA2 INTRON -20 TO +20", "shape": "ellipse"}, {"color": "lightblue", "font": {"color": "black"}, "id": "ARTICLE::Sensitivity and specificity of microRNA-204, CA125, and CA19.9 as biomarkers for diagnosis of ovarian cancer", "label": "Sensitivity and specificity of microRNA-204, CA125, and CA19.9 as biomarkers for diagnosis of ovarian cancer", "shape": "box"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::CHROMOSOME9Q21.12", "label": "CHROMOSOME9Q21.12", "shape": "ellipse"}, {"color": "lightblue", "font": {"color": "black"}, "id": "ARTICLE::Serum levels of tumor markers and their clinical significance in epithelial ovarian cancer", "label": "Serum levels of tumor markers and their clinical significance in epithelial ovarian cancer", "shape": "box"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::CHROMOSOME 19", "label": "CHROMOSOME 19", "shape": "ellipse"}, {"color": "lightblue", "font": {"color": "black"}, "id": "ARTICLE::The Role of Biomarkers in the Management of Epithelial Ovarian Cancer", "label": "The Role of Biomarkers in the Management of Epithelial Ovarian Cancer", "shape": "box"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::CTDNA", "label": "CTDNA", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::LOH", "label": "LOH", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::TAI", "label": "TAI", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::LST", "label": "LST", "shape": "ellipse"}, {"color": "lightblue", "font": {"color": "black"}, "id": "ARTICLE::The Value of Plasma-Based MicroRNAs as Diagnostic Biomarkers for Ovarian Cancer", "label": "The Value of Plasma-Based MicroRNAs as Diagnostic Biomarkers for Ovarian Cancer", "shape": "box"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::SP3", "label": "SP3", "shape": "ellipse"}, {"color": "lightblue", "font": {"color": "black"}, "id": "ARTICLE::The current landscape of predictive and prognostic biomarkers for immune checkpoint blockade in ovarian cancer", "label": "The current landscape of predictive and prognostic biomarkers for immune checkpoint blockade in ovarian cancer", "shape": "box"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::TMB", "label": "TMB", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::FGA", "label": "FGA", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::HRD", "label": "HRD", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::BRCA1 MUTATIONS", "label": "BRCA1 MUTATIONS", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::BRCA2 MUTATIONS", "label": "BRCA2 MUTATIONS", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::ARID1A MUTATION", "label": "ARID1A MUTATION", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::MUTATIONAL SIGNATURE 3", "label": "MUTATIONAL SIGNATURE 3", "shape": "ellipse"}, {"color": "lightblue", "font": {"color": "black"}, "id": "ARTICLE::Sensitive and Cost\u2010Effective Tools in the Detection of Ovarian Cancer Biomarkers", "label": "Sensitive and Cost\u2010Effective Tools in the Detection of Ovarian Cancer Biomarkers", "shape": "box"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::DNA APTAMER", "label": "DNA APTAMER", "shape": "ellipse"}, {"color": "lightblue", "font": {"color": "black"}, "id": "ARTICLE::The role of galectins\u20111, 3, 7, 8 and 9 as potential diagnostic and \r\ntherapeutic markers in ovarian cancer (Review)", "label": "The role of galectins\u20111, 3, 7, 8 and 9 as potential diagnostic and \r\ntherapeutic markers in ovarian cancer (Review)", "shape": "box"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::CHROMOSOME 22Q12", "label": "CHROMOSOME 22Q12", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::CHROMOSOME 1P13", "label": "CHROMOSOME 1P13", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::CHROMOSOME 14Q21-22", "label": "CHROMOSOME 14Q21-22", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::CHROMOSOME 19Q13", "label": "CHROMOSOME 19Q13", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::CHROMOSOME 1Q42.11", "label": "CHROMOSOME 1Q42.11", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::CHROMOSOME 17P11.2", "label": "CHROMOSOME 17P11.2", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::GENOMIC DNA", "label": "GENOMIC DNA", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::33 KB GENOMIC DNA", "label": "33 KB GENOMIC DNA", "shape": "ellipse"}, {"color": "lightblue", "font": {"color": "black"}, "id": "ARTICLE::The role of urine and serum biomarkers in the early detection of ovarian epithelial tumours", "label": "The role of urine and serum biomarkers in the early detection of ovarian epithelial tumours", "shape": "box"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::CIRCULATING TUMOUR DNA", "label": "CIRCULATING TUMOUR DNA", "shape": "ellipse"}, {"color": "lightblue", "font": {"color": "black"}, "id": "ARTICLE::ZNF76 predicts prognosis and response to platinum\r\n chemotherapy in human ovarian cancer", "label": "ZNF76 predicts prognosis and response to platinum\r\n chemotherapy in human ovarian cancer", "shape": "box"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::CHROMOSOME6P21", "label": "CHROMOSOME6P21", "shape": "ellipse"}, {"color": "lightblue", "font": {"color": "black"}, "id": "ARTICLE::Increased circulating tumor DNA as a noninvasive biomarker of early treatment response in patients with metastatic ovarian carcinoma: A pilot study", "label": "Increased circulating tumor DNA as a noninvasive biomarker of early treatment response in patients with metastatic ovarian carcinoma: A pilot study", "shape": "box"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::CIRCULATING FREE DNA (CFDNA)", "label": "CIRCULATING FREE DNA (CFDNA)", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::ALU ELEMENTS", "label": "ALU ELEMENTS", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::ARTHROBACTER LUTEUS ELEMENTS", "label": "ARTHROBACTER LUTEUS ELEMENTS", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::115BP AMPLICONS", "label": "115BP AMPLICONS", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::247BP AMPLICONS", "label": "247BP AMPLICONS", "shape": "ellipse"}, {"color": "lightblue", "font": {"color": "black"}, "id": "ARTICLE::Diagnostic biomarkers in ovarian cancer: advances beyond CA125 and HE4", "label": "Diagnostic biomarkers in ovarian cancer: advances beyond CA125 and HE4", "shape": "box"}, {"color": "lightblue", "font": {"color": "black"}, "id": "ARTICLE::BAI1-Associated Protein 2-Like 1 (BAIAP2L1) Is a Potential Biomarker in Ovarian Cancer", "label": "BAI1-Associated Protein 2-Like 1 (BAIAP2L1) Is a Potential Biomarker in Ovarian Cancer", "shape": "box"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::CHROMOSOME7Q21.3-Q22.1", "label": "CHROMOSOME7Q21.3-Q22.1", "shape": "ellipse"}, {"color": "lightblue", "font": {"color": "black"}, "id": "ARTICLE::Microvesicles as Potential Ovarian Cancer Biomarkers", "label": "Microvesicles as Potential Ovarian Cancer Biomarkers", "shape": "box"}, {"color": "lightblue", "font": {"color": "black"}, "id": "ARTICLE::Biological markers of prognosis, response to therapy and outcome in ovarian carcinoma", "label": "Biological markers of prognosis, response to therapy and outcome in ovarian carcinoma", "shape": "box"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::CIRCULATING CELL-FREE DNA", "label": "CIRCULATING CELL-FREE DNA", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::CIRCULATING TUMOR DNA", "label": "CIRCULATING TUMOR DNA", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::MITOCHONDRIAL DNA", "label": "MITOCHONDRIAL DNA", "shape": "ellipse"}, {"color": "lightblue", "font": {"color": "black"}, "id": "ARTICLE::Biomarkers and Strategies for Early Detection of Ovarian Cancer", "label": "Biomarkers and Strategies for Early Detection of Ovarian Cancer", "shape": "box"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::METHYLATED DNA", "label": "METHYLATED DNA", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::ANEUPLOIDY", "label": "ANEUPLOIDY", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::COPY-NUMBER ABNORMALITIES", "label": "COPY-NUMBER ABNORMALITIES", "shape": "ellipse"}, {"color": "lightblue", "font": {"color": "black"}, "id": "ARTICLE::Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review", "label": "Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review", "shape": "box"}, {"color": "lightblue", "font": {"color": "black"}, "id": "ARTICLE::Biomarkers for Screening, Diagnosis, and Monitoring of\r\n Ovarian Cancer", "label": "Biomarkers for Screening, Diagnosis, and Monitoring of\r\n Ovarian Cancer", "shape": "box"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::CHRXQ27.3", "label": "CHRXQ27.3", "shape": "ellipse"}, {"color": "lightblue", "font": {"color": "black"}, "id": "ARTICLE::CD24 expression is a marker for predicting clinical outcome \r\nand regulates the epithelial-mesenchymal transition in \r\novarian cancer via both the Akt and ERK pathways", "label": "CD24 expression is a marker for predicting clinical outcome \r\nand regulates the epithelial-mesenchymal transition in \r\novarian cancer via both the Akt and ERK pathways", "shape": "box"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::PEZ-M02-CD24", "label": "PEZ-M02-CD24", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::TRILENCER-27 CD24 SIRNA PLASMID", "label": "TRILENCER-27 CD24 SIRNA PLASMID", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::SCRAMBLED SEQUENCE NEGATIVE CONTROL PLASMID", "label": "SCRAMBLED SEQUENCE NEGATIVE CONTROL PLASMID", "shape": "ellipse"}, {"color": "lightblue", "font": {"color": "black"}, "id": "ARTICLE::CX3CR1 is a potential biomarker of immune \r\nmicroenvironment and prognosis in epithelial \r\novarian cancer", "label": "CX3CR1 is a potential biomarker of immune \r\nmicroenvironment and prognosis in epithelial \r\novarian cancer", "shape": "box"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::3P22.2", "label": "3P22.2", "shape": "ellipse"}, {"color": "lightblue", "font": {"color": "black"}, "id": "ARTICLE::A comprehensive overview of exosomes in ovarian cancer: emerging biomarkers and therapeutic strategies", "label": "A comprehensive overview of exosomes in ovarian cancer: emerging biomarkers and therapeutic strategies", "shape": "box"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::DOUBLE-STRANDED DNA", "label": "DOUBLE-STRANDED DNA", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::MTDNA", "label": "MTDNA", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::EXODNA", "label": "EXODNA", "shape": "ellipse"}, {"color": "lightblue", "font": {"color": "black"}, "id": "ARTICLE::CXCR4 knockdown enhances sensitivity of paclitaxel via the \r\nPI3K/Akt/mTOR pathway in ovarian carcinoma", "label": "CXCR4 knockdown enhances sensitivity of paclitaxel via the \r\nPI3K/Akt/mTOR pathway in ovarian carcinoma", "shape": "box"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::CXCR4", "label": "CXCR4", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::CXCL12", "label": "CXCL12", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::CXCR4 CDNA PLASMID", "label": "CXCR4 CDNA PLASMID", "shape": "ellipse"}, {"color": "lightblue", "font": {"color": "black"}, "id": "ARTICLE::Biomarkers in ovarian cancer: To be or not to be", "label": "Biomarkers in ovarian cancer: To be or not to be", "shape": "box"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::CHROMOSOME", "label": "CHROMOSOME", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::GENOME", "label": "GENOME", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::GENOME-WIDE LOSS OF HETEROZYGOSITY", "label": "GENOME-WIDE LOSS OF HETEROZYGOSITY", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::TELOMERIC ALLELIC IMBALANCE", "label": "TELOMERIC ALLELIC IMBALANCE", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::CHROMOSOMAL BREAKS", "label": "CHROMOSOMAL BREAKS", "shape": "ellipse"}, {"color": "lightblue", "font": {"color": "black"}, "id": "ARTICLE::Circulating Cell Free DNA as the Diagnostic Marker for Ovarian Cancer: A Systematic Review and Meta-Analysis", "label": "Circulating Cell Free DNA as the Diagnostic Marker for Ovarian Cancer: A Systematic Review and Meta-Analysis", "shape": "box"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::CIRCULATING CELL-FREE DNA (CFDNA)", "label": "CIRCULATING CELL-FREE DNA (CFDNA)", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::CELL-FREE DNA", "label": "CELL-FREE DNA", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::CFDNA", "label": "CFDNA", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::PLASMA DNA", "label": "PLASMA DNA", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::SERUM CFDNA", "label": "SERUM CFDNA", "shape": "ellipse"}, {"color": "lightblue", "font": {"color": "black"}, "id": "ARTICLE::Circulating tumor DNA: a noninvasive biomarker for tracking ovarian cancer", "label": "Circulating tumor DNA: a noninvasive biomarker for tracking ovarian cancer", "shape": "box"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::DNA FRAGMENTS (150-200 BP)", "label": "DNA FRAGMENTS (150-200 BP)", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::TUMOR GENOME", "label": "TUMOR GENOME", "shape": "ellipse"}, {"color": "lightblue", "font": {"color": "black"}, "id": "ARTICLE::Comprehensive analysis of TLX2 in pan cancer as a prognostic and immunologic biomarker and validation in ovarian cancer", "label": "Comprehensive analysis of TLX2 in pan cancer as a prognostic and immunologic biomarker and validation in ovarian cancer", "shape": "box"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::TLX2 LOCUS", "label": "TLX2 LOCUS", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::TERT PROMOTER", "label": "TERT PROMOTER", "shape": "ellipse"}, {"color": "lightblue", "font": {"color": "black"}, "id": "ARTICLE::Desmoglein-2 as a prognostic and biomarker in ovarian cancer", "label": "Desmoglein-2 as a prognostic and biomarker in ovarian cancer", "shape": "box"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::ADENOVIRUS", "label": "ADENOVIRUS", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::AD5", "label": "AD5", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::3", "label": "3", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::AD3", "label": "AD3", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::AD14", "label": "AD14", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::AD14P1", "label": "AD14P1", "shape": "ellipse"}, {"color": "lightblue", "font": {"color": "black"}, "id": "ARTICLE::Diagnostic role of urine human epididymis protein 4 in ovarian cancer", "label": "Diagnostic role of urine human epididymis protein 4 in ovarian cancer", "shape": "box"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::CHROMOSOME 20Q12", "label": "CHROMOSOME 20Q12", "shape": "ellipse"}, {"color": "lightblue", "font": {"color": "black"}, "id": "ARTICLE::Discovery of a biomarker candidate for surgical stratification in high-grade serous ovarian cancer", "label": "Discovery of a biomarker candidate for surgical stratification in high-grade serous ovarian cancer", "shape": "box"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::MYLK3 PROMOTER METHYLATION", "label": "MYLK3 PROMOTER METHYLATION", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::CCNE1 AMPLIFICATION", "label": "CCNE1 AMPLIFICATION", "shape": "ellipse"}, {"color": "lightblue", "font": {"color": "black"}, "id": "ARTICLE::Early diagnosis of ovarian cancer based on methylation profiles in peripheral blood cell-free DNA: a systematic review", "label": "Early diagnosis of ovarian cancer based on methylation profiles in peripheral blood cell-free DNA: a systematic review", "shape": "box"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::CELL-FREE DNA (CFDNA)", "label": "CELL-FREE DNA (CFDNA)", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::DNA METHYLATION", "label": "DNA METHYLATION", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::PROMOTER REGIONS", "label": "PROMOTER REGIONS", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::CPG ISLANDS", "label": "CPG ISLANDS", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::CPGS", "label": "CPGS", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::BISULFITE CONVERSION", "label": "BISULFITE CONVERSION", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::DNA METHYLATION BIOMARKERS", "label": "DNA METHYLATION BIOMARKERS", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::DNA METHYLATION-BASED DETECTION MARKERS", "label": "DNA METHYLATION-BASED DETECTION MARKERS", "shape": "ellipse"}, {"color": "lightblue", "font": {"color": "black"}, "id": "ARTICLE::Epithelial ovarian cancer and the use of circulating tumor DNA: A systematic review", "label": "Epithelial ovarian cancer and the use of circulating tumor DNA: A systematic review", "shape": "box"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::TUMOR DNA", "label": "TUMOR DNA", "shape": "ellipse"}, {"color": "lightblue", "font": {"color": "black"}, "id": "ARTICLE::Extracellular vesicles in ovarian cancer chemoresistance, metastasis, and immune evasion", "label": "Extracellular vesicles in ovarian cancer chemoresistance, metastasis, and immune evasion", "shape": "box"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::DNAS", "label": "DNAS", "shape": "ellipse"}, {"color": "lightblue", "font": {"color": "black"}, "id": "ARTICLE::Genetic characterization of early onset ovarian carcinoma", "label": "Genetic characterization of early onset ovarian carcinoma", "shape": "box"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::GERMLINE DNA", "label": "GERMLINE DNA", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::HG19", "label": "HG19", "shape": "ellipse"}, {"color": "lightblue", "font": {"color": "black"}, "id": "ARTICLE::HE4 level in ascites may assess the ovarian cancer chemotherapeutic effect", "label": "HE4 level in ascites may assess the ovarian cancer chemotherapeutic effect", "shape": "box"}, {"color": "lightblue", "font": {"color": "black"}, "id": "ARTICLE::Helicase POLQ-like (HELQ) as a novel indicator of platinum-based chemoresistance for epithelial ovarian cancer", "label": "Helicase POLQ-like (HELQ) as a novel indicator of platinum-based chemoresistance for epithelial ovarian cancer", "shape": "box"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::4Q21", "label": "4Q21", "shape": "ellipse"}, {"color": "lightblue", "font": {"color": "black"}, "id": "ARTICLE::High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma", "label": "High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma", "shape": "box"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::19 P13", "label": "19 P13", "shape": "ellipse"}, {"color": "lightblue", "font": {"color": "black"}, "id": "ARTICLE::Identification of PKP 2/3 as potential biomarkers of ovarian cancer based on bioinformatics and experiments", "label": "Identification of PKP 2/3 as potential biomarkers of ovarian cancer based on bioinformatics and experiments", "shape": "box"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::DNA COPY NUMBER CHANGES", "label": "DNA COPY NUMBER CHANGES", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::CNAS", "label": "CNAS", "shape": "ellipse"}, {"color": "lightblue", "font": {"color": "black"}, "id": "ARTICLE::Kallikrein expression as a prognostic factor in ovarian cancer: \r\na systematic review and meta-analysis", "label": "Kallikrein expression as a prognostic factor in ovarian cancer: \r\na systematic review and meta-analysis", "shape": "box"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::CHROMOSOME 19Q13.3-Q13.4", "label": "CHROMOSOME 19Q13.3-Q13.4", "shape": "ellipse"}, {"color": "lightblue", "font": {"color": "black"}, "id": "ARTICLE::Low EIF2B5 expression predicts poor prognosis in\r\n ovarian cancer", "label": "Low EIF2B5 expression predicts poor prognosis in\r\n ovarian cancer", "shape": "box"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::EIF2B5 EXON 2", "label": "EIF2B5 EXON 2", "shape": "ellipse"}, {"color": "lightblue", "font": {"color": "black"}, "id": "ARTICLE::Metabonomics study of the serum from ovarian cancer patients", "label": "Metabonomics study of the serum from ovarian cancer patients", "shape": "box"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::CHROMOSOME 11", "label": "CHROMOSOME 11", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::APOA1", "label": "APOA1", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::C3", "label": "C3", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::A4", "label": "A4", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::A5 GENE CLUSTER", "label": "A5 GENE CLUSTER", "shape": "ellipse"}, {"color": "lightblue", "font": {"color": "black"}, "id": "ARTICLE::MicroRNA: a new and promising potential biomarker for \r\ndiagnosis and prognosis of ovarian cancer", "label": "MicroRNA: a new and promising potential biomarker for \r\ndiagnosis and prognosis of ovarian cancer", "shape": "box"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::CHROMOSOME 12", "label": "CHROMOSOME 12", "shape": "ellipse"}, {"color": "lightblue", "font": {"color": "black"}, "id": "ARTICLE::MicroRNAs as Potential Biomarkers in Gynecological Cancers", "label": "MicroRNAs as Potential Biomarkers in Gynecological Cancers", "shape": "box"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::HPV DNA", "label": "HPV DNA", "shape": "ellipse"}, {"color": "lightblue", "font": {"color": "black"}, "id": "ARTICLE::Overexpression of CHI3L1 is associated with chemoresistance \r\nand poor outcome of epithelial ovarian carcinoma", "label": "Overexpression of CHI3L1 is associated with chemoresistance \r\nand poor outcome of epithelial ovarian carcinoma", "shape": "box"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::CHROMOSOME 1Q32.1", "label": "CHROMOSOME 1Q32.1", "shape": "ellipse"}, {"color": "lightblue", "font": {"color": "black"}, "id": "ARTICLE::Overexpression of HE4 (human epididymis protein 4) enhances \r\nproliferation, invasion and metastasis of ovarian cancer", "label": "Overexpression of HE4 (human epididymis protein 4) enhances \r\nproliferation, invasion and metastasis of ovarian cancer", "shape": "box"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::WFDC2", "label": "WFDC2", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::HE4 DNA APTAMERS", "label": "HE4 DNA APTAMERS", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::DNA OLIGONUCLEOTIDE PROBES", "label": "DNA OLIGONUCLEOTIDE PROBES", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::OVARIAN CDNAS", "label": "OVARIAN CDNAS", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::CDNA MICROARRAYS", "label": "CDNA MICROARRAYS", "shape": "ellipse"}, {"color": "lightblue", "font": {"color": "black"}, "id": "ARTICLE::Overexpression of ICAM-1 Predicts Poor Survival in\r\n High-Grade Serous Ovarian Carcinoma: A Study Based on\r\n TCGAandGEODatabases and Tissue Microarray", "label": "Overexpression of ICAM-1 Predicts Poor Survival in\r\n High-Grade Serous Ovarian Carcinoma: A Study Based on\r\n TCGAandGEODatabases and Tissue Microarray", "shape": "box"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::ICAM1", "label": "ICAM1", "shape": "ellipse"}, {"color": "lightblue", "font": {"color": "black"}, "id": "ARTICLE::Overexpression of the recently identified oncogene REDD1 correlates with tumor progression and is an independent unfavorable prognostic factor for ovarian carcinoma", "label": "Overexpression of the recently identified oncogene REDD1 correlates with tumor progression and is an independent unfavorable prognostic factor for ovarian carcinoma", "shape": "box"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::CHROMOSOME 10Q24.33", "label": "CHROMOSOME 10Q24.33", "shape": "ellipse"}, {"color": "lightblue", "font": {"color": "black"}, "id": "ARTICLE::PSMD8 can serve as potential biomarker and therapeutic target of the PSMD family in ovarian cancer: based on bioinformatics analysis and in vitro validation", "label": "PSMD8 can serve as potential biomarker and therapeutic target of the PSMD family in ovarian cancer: based on bioinformatics analysis and in vitro validation", "shape": "box"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::DNA COPIES", "label": "DNA COPIES", "shape": "ellipse"}, {"color": "lightblue", "font": {"color": "black"}, "id": "ARTICLE::Pathogenicity of PKC Genetic Variants\u2014Possible Function as a Non-Invasive Diagnostic Biomarker in Ovarian Cancer", "label": "Pathogenicity of PKC Genetic Variants\u2014Possible Function as a Non-Invasive Diagnostic Biomarker in Ovarian Cancer", "shape": "box"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::19Q13.2-Q13.4", "label": "19Q13.2-Q13.4", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::RS923331350", "label": "RS923331350", "shape": "ellipse"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::RS1331232028", "label": "RS1331232028", "shape": "ellipse"}, {"color": "lightblue", "font": {"color": "black"}, "id": "ARTICLE::Peroxiredoxin-1 as a prognostic factor  in \r\npatients with ovarian cancer", "label": "Peroxiredoxin-1 as a prognostic factor  in \r\npatients with ovarian cancer", "shape": "box"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::COX-2 UPSTREAM PROMOTER ELEMENTS", "label": "COX-2 UPSTREAM PROMOTER ELEMENTS", "shape": "ellipse"}, {"color": "lightblue", "font": {"color": "black"}, "id": "ARTICLE::Preoperative ctDNA Levels Are Associated With Poor Overall Survival in Patients With Ovarian Cancer", "label": "Preoperative ctDNA Levels Are Associated With Poor Overall Survival in Patients With Ovarian Cancer", "shape": "box"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::HG38", "label": "HG38", "shape": "ellipse"}, {"color": "lightblue", "font": {"color": "black"}, "id": "ARTICLE::Prognostic value of abnormally expressed lncRNAs in ovarian \r\ncarcinoma: a systematic review and meta-analysis", "label": "Prognostic value of abnormally expressed lncRNAs in ovarian \r\ncarcinoma: a systematic review and meta-analysis", "shape": "box"}, {"color": "lightgreen", "font": {"color": "black"}, "id": "DNA::HOXC LOCUS", "label": "HOXC LOCUS", "shape": "ellipse"}, {"color": "lightblue", "font": {"color": "black"}, "id": "ARTICLE::Proteomic and lipidomic analysis of exosomes derived from ovarian cancer cells and ovarian surface epithelial cells", "label": "Proteomic and lipidomic analysis of exosomes derived from ovarian cancer cells and ovarian surface epithelial cells", "shape": "box"}]);
                  edges = new vis.DataSet([{"from": "ARTICLE::A Perspective on Ovarian Cancer Biomarkers: Past, Present and Yet-To-Come", "to": "DNA::FREE DNA"}, {"from": "ARTICLE::A Perspective on Ovarian Cancer Biomarkers: Past, Present and Yet-To-Come", "to": "DNA::CIRCULATING TUMOR DNA (CTDNA)"}, {"from": "ARTICLE::AhRR and PPP1R3C: Potential Prognostic Biomarkers for Serous Ovarian Cancer", "to": "DNA::5P15.33"}, {"from": "ARTICLE::AhRR and PPP1R3C: Potential Prognostic Biomarkers for Serous Ovarian Cancer", "to": "DNA::CHROMOSOME 5"}, {"from": "ARTICLE::RNA biomarkers from proximal liquid biopsy for diagnosis of ovarian cancer", "to": "DNA::20Q12-Q13"}, {"from": "ARTICLE::Recent Advances in Ovarian Cancer: Therapeutic Strategies, Potential Biomarkers, and Technological Improvements", "to": "DNA::CPG ISLAND"}, {"from": "ARTICLE::Recent Insight about HE4 Role in Ovarian Cancer Oncogenesis", "to": "DNA::CHROMOSOME 20Q12-13.1"}, {"from": "ARTICLE::Role of Circulating Biomarkers in Platinum-Resistant Ovarian Cancer", "to": "DNA::CHROMOSOME 16P13.3"}, {"from": "ARTICLE::Role of Circulating Biomarkers in Platinum-Resistant Ovarian Cancer", "to": "DNA::CHROMOSOME 17"}, {"from": "ARTICLE::Role of Circulating Biomarkers in Platinum-Resistant Ovarian Cancer", "to": "DNA::CPG SITES"}, {"from": "ARTICLE::Role of biomarkers for early detection of ovarian cancer \r\nrecurrence", "to": "DNA::CDNA"}, {"from": "ARTICLE::Role of different non-coding RNAs as ovarian Cancer biomarkers", "to": "DNA::H19_CHR11P15.5"}, {"from": "ARTICLE::Role of different non-coding RNAs as ovarian Cancer biomarkers", "to": "DNA::HOTAIR_CHR12Q13.13"}, {"from": "ARTICLE::Role of different non-coding RNAs as ovarian Cancer biomarkers", "to": "DNA::XIST_CHRX"}, {"from": "ARTICLE::Role of different non-coding RNAs as ovarian Cancer biomarkers", "to": "DNA::UCA1_CHR19P13.12"}, {"from": "ARTICLE::Role of different non-coding RNAs as ovarian Cancer biomarkers", "to": "DNA::MALAT1_CHR11Q13"}, {"from": "ARTICLE::Role of different non-coding RNAs as ovarian Cancer biomarkers", "to": "DNA::PVT1_CHR8Q24.21"}, {"from": "ARTICLE::Role of different non-coding RNAs as ovarian Cancer biomarkers", "to": "DNA::GAS5_1Q25.1.10"}, {"from": "ARTICLE::Role of different non-coding RNAs as ovarian Cancer biomarkers", "to": "DNA::HOXD-AS1_CHR2Q31.2"}, {"from": "ARTICLE::Role of different non-coding RNAs as ovarian Cancer biomarkers", "to": "DNA::SPRY4-IT1_CHR5Q31.3"}, {"from": "ARTICLE::Role of lncRNAs in ovarian cancer: defining new biomarkers for therapeutic purposes", "to": "DNA::CHROMOSOME 1"}, {"from": "ARTICLE::Role of lncRNAs in ovarian cancer: defining new biomarkers for therapeutic purposes", "to": "DNA::8Q24"}, {"from": "ARTICLE::Analysis of Circulating Tumor Cells in \r\nOvarian Cancer and Their Clinical Value as a \r\nBiomarker", "to": "DNA::CIRCULATING FREE DNA"}, {"from": "ARTICLE::Novel BRCA1 and BRCA2 Tumor Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas", "to": "DNA::BRCA1 PROMOTER"}, {"from": "ARTICLE::Novel BRCA1 and BRCA2 Tumor Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas", "to": "DNA::BRCA1 EXON 22"}, {"from": "ARTICLE::Novel BRCA1 and BRCA2 Tumor Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas", "to": "DNA::BRCA1 INTRON -20 TO +20"}, {"from": "ARTICLE::Novel BRCA1 and BRCA2 Tumor Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas", "to": "DNA::BRCA1 LOCUS"}, {"from": "ARTICLE::Novel BRCA1 and BRCA2 Tumor Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas", "to": "DNA::BRCA2 LOCUS"}, {"from": "ARTICLE::Novel BRCA1 and BRCA2 Tumor Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas", "to": "DNA::BRCA2 INTRON -20 TO +20"}, {"from": "ARTICLE::Sensitivity and specificity of microRNA-204, CA125, and CA19.9 as biomarkers for diagnosis of ovarian cancer", "to": "DNA::CHROMOSOME9Q21.12"}, {"from": "ARTICLE::Serum levels of tumor markers and their clinical significance in epithelial ovarian cancer", "to": "DNA::CHROMOSOME 19"}, {"from": "ARTICLE::The Role of Biomarkers in the Management of Epithelial Ovarian Cancer", "to": "DNA::CTDNA"}, {"from": "ARTICLE::The Role of Biomarkers in the Management of Epithelial Ovarian Cancer", "to": "DNA::LOH"}, {"from": "ARTICLE::The Role of Biomarkers in the Management of Epithelial Ovarian Cancer", "to": "DNA::TAI"}, {"from": "ARTICLE::The Role of Biomarkers in the Management of Epithelial Ovarian Cancer", "to": "DNA::LST"}, {"from": "ARTICLE::The Value of Plasma-Based MicroRNAs as Diagnostic Biomarkers for Ovarian Cancer", "to": "DNA::SP3"}, {"from": "ARTICLE::The current landscape of predictive and prognostic biomarkers for immune checkpoint blockade in ovarian cancer", "to": "DNA::CTDNA"}, {"from": "ARTICLE::The current landscape of predictive and prognostic biomarkers for immune checkpoint blockade in ovarian cancer", "to": "DNA::TMB"}, {"from": "ARTICLE::The current landscape of predictive and prognostic biomarkers for immune checkpoint blockade in ovarian cancer", "to": "DNA::FGA"}, {"from": "ARTICLE::The current landscape of predictive and prognostic biomarkers for immune checkpoint blockade in ovarian cancer", "to": "DNA::HRD"}, {"from": "ARTICLE::The current landscape of predictive and prognostic biomarkers for immune checkpoint blockade in ovarian cancer", "to": "DNA::BRCA1 MUTATIONS"}, {"from": "ARTICLE::The current landscape of predictive and prognostic biomarkers for immune checkpoint blockade in ovarian cancer", "to": "DNA::BRCA2 MUTATIONS"}, {"from": "ARTICLE::The current landscape of predictive and prognostic biomarkers for immune checkpoint blockade in ovarian cancer", "to": "DNA::ARID1A MUTATION"}, {"from": "ARTICLE::The current landscape of predictive and prognostic biomarkers for immune checkpoint blockade in ovarian cancer", "to": "DNA::MUTATIONAL SIGNATURE 3"}, {"from": "ARTICLE::Sensitive and Cost\u2010Effective Tools in the Detection of Ovarian Cancer Biomarkers", "to": "DNA::CTDNA"}, {"from": "ARTICLE::Sensitive and Cost\u2010Effective Tools in the Detection of Ovarian Cancer Biomarkers", "to": "DNA::DNA APTAMER"}, {"from": "ARTICLE::The role of galectins\u20111, 3, 7, 8 and 9 as potential diagnostic and \r\ntherapeutic markers in ovarian cancer (Review)", "to": "DNA::CHROMOSOME 22Q12"}, {"from": "ARTICLE::The role of galectins\u20111, 3, 7, 8 and 9 as potential diagnostic and \r\ntherapeutic markers in ovarian cancer (Review)", "to": "DNA::CHROMOSOME 1P13"}, {"from": "ARTICLE::The role of galectins\u20111, 3, 7, 8 and 9 as potential diagnostic and \r\ntherapeutic markers in ovarian cancer (Review)", "to": "DNA::CHROMOSOME 14Q21-22"}, {"from": "ARTICLE::The role of galectins\u20111, 3, 7, 8 and 9 as potential diagnostic and \r\ntherapeutic markers in ovarian cancer (Review)", "to": "DNA::CHROMOSOME 19Q13"}, {"from": "ARTICLE::The role of galectins\u20111, 3, 7, 8 and 9 as potential diagnostic and \r\ntherapeutic markers in ovarian cancer (Review)", "to": "DNA::CHROMOSOME 1Q42.11"}, {"from": "ARTICLE::The role of galectins\u20111, 3, 7, 8 and 9 as potential diagnostic and \r\ntherapeutic markers in ovarian cancer (Review)", "to": "DNA::CHROMOSOME 17P11.2"}, {"from": "ARTICLE::The role of galectins\u20111, 3, 7, 8 and 9 as potential diagnostic and \r\ntherapeutic markers in ovarian cancer (Review)", "to": "DNA::GENOMIC DNA"}, {"from": "ARTICLE::The role of galectins\u20111, 3, 7, 8 and 9 as potential diagnostic and \r\ntherapeutic markers in ovarian cancer (Review)", "to": "DNA::33 KB GENOMIC DNA"}, {"from": "ARTICLE::The role of urine and serum biomarkers in the early detection of ovarian epithelial tumours", "to": "DNA::CIRCULATING TUMOUR DNA"}, {"from": "ARTICLE::The role of urine and serum biomarkers in the early detection of ovarian epithelial tumours", "to": "DNA::CTDNA"}, {"from": "ARTICLE::The role of urine and serum biomarkers in the early detection of ovarian epithelial tumours", "to": "DNA::FREE DNA"}, {"from": "ARTICLE::ZNF76 predicts prognosis and response to platinum\r\n chemotherapy in human ovarian cancer", "to": "DNA::CHROMOSOME6P21"}, {"from": "ARTICLE::Increased circulating tumor DNA as a noninvasive biomarker of early treatment response in patients with metastatic ovarian carcinoma: A pilot study", "to": "DNA::CIRCULATING TUMOR DNA (CTDNA)"}, {"from": "ARTICLE::Increased circulating tumor DNA as a noninvasive biomarker of early treatment response in patients with metastatic ovarian carcinoma: A pilot study", "to": "DNA::CIRCULATING FREE DNA (CFDNA)"}, {"from": "ARTICLE::Increased circulating tumor DNA as a noninvasive biomarker of early treatment response in patients with metastatic ovarian carcinoma: A pilot study", "to": "DNA::ALU ELEMENTS"}, {"from": "ARTICLE::Increased circulating tumor DNA as a noninvasive biomarker of early treatment response in patients with metastatic ovarian carcinoma: A pilot study", "to": "DNA::ARTHROBACTER LUTEUS ELEMENTS"}, {"from": "ARTICLE::Increased circulating tumor DNA as a noninvasive biomarker of early treatment response in patients with metastatic ovarian carcinoma: A pilot study", "to": "DNA::115BP AMPLICONS"}, {"from": "ARTICLE::Increased circulating tumor DNA as a noninvasive biomarker of early treatment response in patients with metastatic ovarian carcinoma: A pilot study", "to": "DNA::247BP AMPLICONS"}, {"from": "ARTICLE::Diagnostic biomarkers in ovarian cancer: advances beyond CA125 and HE4", "to": "DNA::CIRCULATING TUMOR DNA (CTDNA)"}, {"from": "ARTICLE::BAI1-Associated Protein 2-Like 1 (BAIAP2L1) Is a Potential Biomarker in Ovarian Cancer", "to": "DNA::CHROMOSOME7Q21.3-Q22.1"}, {"from": "ARTICLE::Microvesicles as Potential Ovarian Cancer Biomarkers", "to": "DNA::GENOMIC DNA"}, {"from": "ARTICLE::Biological markers of prognosis, response to therapy and outcome in ovarian carcinoma", "to": "DNA::CIRCULATING CELL-FREE DNA"}, {"from": "ARTICLE::Biological markers of prognosis, response to therapy and outcome in ovarian carcinoma", "to": "DNA::CIRCULATING TUMOR DNA"}, {"from": "ARTICLE::Biological markers of prognosis, response to therapy and outcome in ovarian carcinoma", "to": "DNA::MITOCHONDRIAL DNA"}, {"from": "ARTICLE::Biomarkers and Strategies for Early Detection of Ovarian Cancer", "to": "DNA::CTDNA"}, {"from": "ARTICLE::Biomarkers and Strategies for Early Detection of Ovarian Cancer", "to": "DNA::METHYLATED DNA"}, {"from": "ARTICLE::Biomarkers and Strategies for Early Detection of Ovarian Cancer", "to": "DNA::ANEUPLOIDY"}, {"from": "ARTICLE::Biomarkers and Strategies for Early Detection of Ovarian Cancer", "to": "DNA::COPY-NUMBER ABNORMALITIES"}, {"from": "ARTICLE::Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review", "to": "DNA::CHROMOSOME 20Q12-13.1"}, {"from": "ARTICLE::Biomarkers for Screening, Diagnosis, and Monitoring of\r\n Ovarian Cancer", "to": "DNA::CPG ISLAND"}, {"from": "ARTICLE::Biomarkers for Screening, Diagnosis, and Monitoring of\r\n Ovarian Cancer", "to": "DNA::CHRXQ27.3"}, {"from": "ARTICLE::CD24 expression is a marker for predicting clinical outcome \r\nand regulates the epithelial-mesenchymal transition in \r\novarian cancer via both the Akt and ERK pathways", "to": "DNA::PEZ-M02-CD24"}, {"from": "ARTICLE::CD24 expression is a marker for predicting clinical outcome \r\nand regulates the epithelial-mesenchymal transition in \r\novarian cancer via both the Akt and ERK pathways", "to": "DNA::TRILENCER-27 CD24 SIRNA PLASMID"}, {"from": "ARTICLE::CD24 expression is a marker for predicting clinical outcome \r\nand regulates the epithelial-mesenchymal transition in \r\novarian cancer via both the Akt and ERK pathways", "to": "DNA::SCRAMBLED SEQUENCE NEGATIVE CONTROL PLASMID"}, {"from": "ARTICLE::CX3CR1 is a potential biomarker of immune \r\nmicroenvironment and prognosis in epithelial \r\novarian cancer", "to": "DNA::3P22.2"}, {"from": "ARTICLE::A comprehensive overview of exosomes in ovarian cancer: emerging biomarkers and therapeutic strategies", "to": "DNA::DOUBLE-STRANDED DNA"}, {"from": "ARTICLE::A comprehensive overview of exosomes in ovarian cancer: emerging biomarkers and therapeutic strategies", "to": "DNA::GENOMIC DNA"}, {"from": "ARTICLE::A comprehensive overview of exosomes in ovarian cancer: emerging biomarkers and therapeutic strategies", "to": "DNA::MTDNA"}, {"from": "ARTICLE::A comprehensive overview of exosomes in ovarian cancer: emerging biomarkers and therapeutic strategies", "to": "DNA::EXODNA"}, {"from": "ARTICLE::A comprehensive overview of exosomes in ovarian cancer: emerging biomarkers and therapeutic strategies", "to": "DNA::CDNA"}, {"from": "ARTICLE::CXCR4 knockdown enhances sensitivity of paclitaxel via the \r\nPI3K/Akt/mTOR pathway in ovarian carcinoma", "to": "DNA::CXCR4"}, {"from": "ARTICLE::CXCR4 knockdown enhances sensitivity of paclitaxel via the \r\nPI3K/Akt/mTOR pathway in ovarian carcinoma", "to": "DNA::CXCL12"}, {"from": "ARTICLE::CXCR4 knockdown enhances sensitivity of paclitaxel via the \r\nPI3K/Akt/mTOR pathway in ovarian carcinoma", "to": "DNA::CXCR4 CDNA PLASMID"}, {"from": "ARTICLE::Biomarkers in ovarian cancer: To be or not to be", "to": "DNA::CHROMOSOME"}, {"from": "ARTICLE::Biomarkers in ovarian cancer: To be or not to be", "to": "DNA::GENOME"}, {"from": "ARTICLE::Biomarkers in ovarian cancer: To be or not to be", "to": "DNA::GENOME-WIDE LOSS OF HETEROZYGOSITY"}, {"from": "ARTICLE::Biomarkers in ovarian cancer: To be or not to be", "to": "DNA::TELOMERIC ALLELIC IMBALANCE"}, {"from": "ARTICLE::Biomarkers in ovarian cancer: To be or not to be", "to": "DNA::CHROMOSOMAL BREAKS"}, {"from": "ARTICLE::Circulating Cell Free DNA as the Diagnostic Marker for Ovarian Cancer: A Systematic Review and Meta-Analysis", "to": "DNA::CIRCULATING CELL-FREE DNA (CFDNA)"}, {"from": "ARTICLE::Circulating Cell Free DNA as the Diagnostic Marker for Ovarian Cancer: A Systematic Review and Meta-Analysis", "to": "DNA::CELL-FREE DNA"}, {"from": "ARTICLE::Circulating Cell Free DNA as the Diagnostic Marker for Ovarian Cancer: A Systematic Review and Meta-Analysis", "to": "DNA::CFDNA"}, {"from": "ARTICLE::Circulating Cell Free DNA as the Diagnostic Marker for Ovarian Cancer: A Systematic Review and Meta-Analysis", "to": "DNA::PLASMA DNA"}, {"from": "ARTICLE::Circulating Cell Free DNA as the Diagnostic Marker for Ovarian Cancer: A Systematic Review and Meta-Analysis", "to": "DNA::SERUM CFDNA"}, {"from": "ARTICLE::Circulating tumor DNA: a noninvasive biomarker for tracking ovarian cancer", "to": "DNA::CTDNA"}, {"from": "ARTICLE::Circulating tumor DNA: a noninvasive biomarker for tracking ovarian cancer", "to": "DNA::CFDNA"}, {"from": "ARTICLE::Circulating tumor DNA: a noninvasive biomarker for tracking ovarian cancer", "to": "DNA::DNA FRAGMENTS (150-200 BP)"}, {"from": "ARTICLE::Circulating tumor DNA: a noninvasive biomarker for tracking ovarian cancer", "to": "DNA::TUMOR GENOME"}, {"from": "ARTICLE::Comprehensive analysis of TLX2 in pan cancer as a prognostic and immunologic biomarker and validation in ovarian cancer", "to": "DNA::TLX2 LOCUS"}, {"from": "ARTICLE::Comprehensive analysis of TLX2 in pan cancer as a prognostic and immunologic biomarker and validation in ovarian cancer", "to": "DNA::TERT PROMOTER"}, {"from": "ARTICLE::Desmoglein-2 as a prognostic and biomarker in ovarian cancer", "to": "DNA::ADENOVIRUS"}, {"from": "ARTICLE::Desmoglein-2 as a prognostic and biomarker in ovarian cancer", "to": "DNA::AD5"}, {"from": "ARTICLE::Desmoglein-2 as a prognostic and biomarker in ovarian cancer", "to": "DNA::3"}, {"from": "ARTICLE::Desmoglein-2 as a prognostic and biomarker in ovarian cancer", "to": "DNA::AD3"}, {"from": "ARTICLE::Desmoglein-2 as a prognostic and biomarker in ovarian cancer", "to": "DNA::AD14"}, {"from": "ARTICLE::Desmoglein-2 as a prognostic and biomarker in ovarian cancer", "to": "DNA::AD14P1"}, {"from": "ARTICLE::Diagnostic role of urine human epididymis protein 4 in ovarian cancer", "to": "DNA::CHROMOSOME 20Q12"}, {"from": "ARTICLE::Discovery of a biomarker candidate for surgical stratification in high-grade serous ovarian cancer", "to": "DNA::MYLK3 PROMOTER METHYLATION"}, {"from": "ARTICLE::Discovery of a biomarker candidate for surgical stratification in high-grade serous ovarian cancer", "to": "DNA::BRCA1 MUTATIONS"}, {"from": "ARTICLE::Discovery of a biomarker candidate for surgical stratification in high-grade serous ovarian cancer", "to": "DNA::BRCA2 MUTATIONS"}, {"from": "ARTICLE::Discovery of a biomarker candidate for surgical stratification in high-grade serous ovarian cancer", "to": "DNA::CCNE1 AMPLIFICATION"}, {"from": "ARTICLE::Early diagnosis of ovarian cancer based on methylation profiles in peripheral blood cell-free DNA: a systematic review", "to": "DNA::CIRCULATING TUMOR DNA (CTDNA)"}, {"from": "ARTICLE::Early diagnosis of ovarian cancer based on methylation profiles in peripheral blood cell-free DNA: a systematic review", "to": "DNA::CELL-FREE DNA (CFDNA)"}, {"from": "ARTICLE::Early diagnosis of ovarian cancer based on methylation profiles in peripheral blood cell-free DNA: a systematic review", "to": "DNA::DNA METHYLATION"}, {"from": "ARTICLE::Early diagnosis of ovarian cancer based on methylation profiles in peripheral blood cell-free DNA: a systematic review", "to": "DNA::PROMOTER REGIONS"}, {"from": "ARTICLE::Early diagnosis of ovarian cancer based on methylation profiles in peripheral blood cell-free DNA: a systematic review", "to": "DNA::CPG ISLANDS"}, {"from": "ARTICLE::Early diagnosis of ovarian cancer based on methylation profiles in peripheral blood cell-free DNA: a systematic review", "to": "DNA::CPGS"}, {"from": "ARTICLE::Early diagnosis of ovarian cancer based on methylation profiles in peripheral blood cell-free DNA: a systematic review", "to": "DNA::BISULFITE CONVERSION"}, {"from": "ARTICLE::Early diagnosis of ovarian cancer based on methylation profiles in peripheral blood cell-free DNA: a systematic review", "to": "DNA::DNA METHYLATION BIOMARKERS"}, {"from": "ARTICLE::Early diagnosis of ovarian cancer based on methylation profiles in peripheral blood cell-free DNA: a systematic review", "to": "DNA::DNA METHYLATION-BASED DETECTION MARKERS"}, {"from": "ARTICLE::Epithelial ovarian cancer and the use of circulating tumor DNA: A systematic review", "to": "DNA::CIRCULATING TUMOR DNA (CTDNA)"}, {"from": "ARTICLE::Epithelial ovarian cancer and the use of circulating tumor DNA: A systematic review", "to": "DNA::CELL-FREE DNA (CFDNA)"}, {"from": "ARTICLE::Epithelial ovarian cancer and the use of circulating tumor DNA: A systematic review", "to": "DNA::TUMOR DNA"}, {"from": "ARTICLE::Extracellular vesicles in ovarian cancer chemoresistance, metastasis, and immune evasion", "to": "DNA::DNAS"}, {"from": "ARTICLE::Genetic characterization of early onset ovarian carcinoma", "to": "DNA::GERMLINE DNA"}, {"from": "ARTICLE::Genetic characterization of early onset ovarian carcinoma", "to": "DNA::HG19"}, {"from": "ARTICLE::HE4 level in ascites may assess the ovarian cancer chemotherapeutic effect", "to": "DNA::CDNA"}, {"from": "ARTICLE::Helicase POLQ-like (HELQ) as a novel indicator of platinum-based chemoresistance for epithelial ovarian cancer", "to": "DNA::4Q21"}, {"from": "ARTICLE::High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma", "to": "DNA::19 P13"}, {"from": "ARTICLE::Identification of PKP 2/3 as potential biomarkers of ovarian cancer based on bioinformatics and experiments", "to": "DNA::DNA COPY NUMBER CHANGES"}, {"from": "ARTICLE::Identification of PKP 2/3 as potential biomarkers of ovarian cancer based on bioinformatics and experiments", "to": "DNA::CNAS"}, {"from": "ARTICLE::Kallikrein expression as a prognostic factor in ovarian cancer: \r\na systematic review and meta-analysis", "to": "DNA::CHROMOSOME 19Q13.3-Q13.4"}, {"from": "ARTICLE::Low EIF2B5 expression predicts poor prognosis in\r\n ovarian cancer", "to": "DNA::EIF2B5 EXON 2"}, {"from": "ARTICLE::Metabonomics study of the serum from ovarian cancer patients", "to": "DNA::CHROMOSOME 11"}, {"from": "ARTICLE::Metabonomics study of the serum from ovarian cancer patients", "to": "DNA::APOA1"}, {"from": "ARTICLE::Metabonomics study of the serum from ovarian cancer patients", "to": "DNA::C3"}, {"from": "ARTICLE::Metabonomics study of the serum from ovarian cancer patients", "to": "DNA::A4"}, {"from": "ARTICLE::Metabonomics study of the serum from ovarian cancer patients", "to": "DNA::A5 GENE CLUSTER"}, {"from": "ARTICLE::MicroRNA: a new and promising potential biomarker for \r\ndiagnosis and prognosis of ovarian cancer", "to": "DNA::CHROMOSOME 1"}, {"from": "ARTICLE::MicroRNA: a new and promising potential biomarker for \r\ndiagnosis and prognosis of ovarian cancer", "to": "DNA::CHROMOSOME 12"}, {"from": "ARTICLE::MicroRNAs as Potential Biomarkers in Gynecological Cancers", "to": "DNA::HPV DNA"}, {"from": "ARTICLE::Overexpression of CHI3L1 is associated with chemoresistance \r\nand poor outcome of epithelial ovarian carcinoma", "to": "DNA::CHROMOSOME 1Q32.1"}, {"from": "ARTICLE::Overexpression of HE4 (human epididymis protein 4) enhances \r\nproliferation, invasion and metastasis of ovarian cancer", "to": "DNA::WFDC2"}, {"from": "ARTICLE::Overexpression of HE4 (human epididymis protein 4) enhances \r\nproliferation, invasion and metastasis of ovarian cancer", "to": "DNA::HE4 DNA APTAMERS"}, {"from": "ARTICLE::Overexpression of HE4 (human epididymis protein 4) enhances \r\nproliferation, invasion and metastasis of ovarian cancer", "to": "DNA::DNA OLIGONUCLEOTIDE PROBES"}, {"from": "ARTICLE::Overexpression of HE4 (human epididymis protein 4) enhances \r\nproliferation, invasion and metastasis of ovarian cancer", "to": "DNA::OVARIAN CDNAS"}, {"from": "ARTICLE::Overexpression of HE4 (human epididymis protein 4) enhances \r\nproliferation, invasion and metastasis of ovarian cancer", "to": "DNA::CDNA MICROARRAYS"}, {"from": "ARTICLE::Overexpression of ICAM-1 Predicts Poor Survival in\r\n High-Grade Serous Ovarian Carcinoma: A Study Based on\r\n TCGAandGEODatabases and Tissue Microarray", "to": "DNA::ICAM1"}, {"from": "ARTICLE::Overexpression of the recently identified oncogene REDD1 correlates with tumor progression and is an independent unfavorable prognostic factor for ovarian carcinoma", "to": "DNA::CHROMOSOME 10Q24.33"}, {"from": "ARTICLE::PSMD8 can serve as potential biomarker and therapeutic target of the PSMD family in ovarian cancer: based on bioinformatics analysis and in vitro validation", "to": "DNA::DNA COPIES"}, {"from": "ARTICLE::PSMD8 can serve as potential biomarker and therapeutic target of the PSMD family in ovarian cancer: based on bioinformatics analysis and in vitro validation", "to": "DNA::DNA METHYLATION"}, {"from": "ARTICLE::Pathogenicity of PKC Genetic Variants\u2014Possible Function as a Non-Invasive Diagnostic Biomarker in Ovarian Cancer", "to": "DNA::CHROMOSOME 19"}, {"from": "ARTICLE::Pathogenicity of PKC Genetic Variants\u2014Possible Function as a Non-Invasive Diagnostic Biomarker in Ovarian Cancer", "to": "DNA::19Q13.2-Q13.4"}, {"from": "ARTICLE::Pathogenicity of PKC Genetic Variants\u2014Possible Function as a Non-Invasive Diagnostic Biomarker in Ovarian Cancer", "to": "DNA::GENOMIC DNA"}, {"from": "ARTICLE::Pathogenicity of PKC Genetic Variants\u2014Possible Function as a Non-Invasive Diagnostic Biomarker in Ovarian Cancer", "to": "DNA::RS923331350"}, {"from": "ARTICLE::Pathogenicity of PKC Genetic Variants\u2014Possible Function as a Non-Invasive Diagnostic Biomarker in Ovarian Cancer", "to": "DNA::RS1331232028"}, {"from": "ARTICLE::Peroxiredoxin-1 as a prognostic factor  in \r\npatients with ovarian cancer", "to": "DNA::GENOMIC DNA"}, {"from": "ARTICLE::Peroxiredoxin-1 as a prognostic factor  in \r\npatients with ovarian cancer", "to": "DNA::COX-2 UPSTREAM PROMOTER ELEMENTS"}, {"from": "ARTICLE::Preoperative ctDNA Levels Are Associated With Poor Overall Survival in Patients With Ovarian Cancer", "to": "DNA::CTDNA"}, {"from": "ARTICLE::Preoperative ctDNA Levels Are Associated With Poor Overall Survival in Patients With Ovarian Cancer", "to": "DNA::CELL-FREE DNA"}, {"from": "ARTICLE::Preoperative ctDNA Levels Are Associated With Poor Overall Survival in Patients With Ovarian Cancer", "to": "DNA::TUMOR DNA"}, {"from": "ARTICLE::Preoperative ctDNA Levels Are Associated With Poor Overall Survival in Patients With Ovarian Cancer", "to": "DNA::HG38"}, {"from": "ARTICLE::Prognostic value of abnormally expressed lncRNAs in ovarian \r\ncarcinoma: a systematic review and meta-analysis", "to": "DNA::HOXC LOCUS"}, {"from": "ARTICLE::Prognostic value of abnormally expressed lncRNAs in ovarian \r\ncarcinoma: a systematic review and meta-analysis", "to": "DNA::CHROMOSOME 12"}, {"from": "ARTICLE::Proteomic and lipidomic analysis of exosomes derived from ovarian cancer cells and ovarian surface epithelial cells", "to": "DNA::DOUBLE-STRANDED DNA"}]);

                  nodeColors = {};
                  allNodes = nodes.get({ returnType: "Object" });
                  for (nodeId in allNodes) {
                    nodeColors[nodeId] = allNodes[nodeId].color;
                  }
                  allEdges = edges.get({ returnType: "Object" });
                  // adding nodes and edges to the graph
                  data = {nodes: nodes, edges: edges};

                  var options = {"interaction": {"hover": false, "tooltipDelay": 999999}};

                  


                  

                  network = new vis.Network(container, data, options);

                  

                  

                  


                  
                      network.on("stabilizationProgress", function(params) {
                          document.getElementById('loadingBar').removeAttribute("style");
                          var maxWidth = 496;
                          var minWidth = 20;
                          var widthFactor = params.iterations/params.total;
                          var width = Math.max(minWidth,maxWidth * widthFactor);
                          document.getElementById('bar').style.width = width + 'px';
                          document.getElementById('text').innerHTML = Math.round(widthFactor*100) + '%';
                      });
                      network.once("stabilizationIterationsDone", function() {
                          document.getElementById('text').innerHTML = '100%';
                          document.getElementById('bar').style.width = '496px';
                          document.getElementById('loadingBar').style.opacity = 0;
                          // really clean the dom element
                          setTimeout(function () {document.getElementById('loadingBar').style.display = 'none';}, 500);
                      });
                  

                  return network;

              }
              drawGraph();
        </script>
    </body>
</html>